Cargando…
Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319730/ https://www.ncbi.nlm.nih.gov/pubmed/30608991 http://dx.doi.org/10.1371/journal.pone.0210593 |
| _version_ | 1783385115807711232 |
|---|---|
| author | Bekker, Pirow Dairaghi, Daniel Seitz, Lisa Leleti, Manmohan Wang, Yu Ertl, Linda Baumgart, Trageen Shugarts, Sarah Lohr, Lisa Dang, Ton Miao, Shichang Zeng, Yibin Fan, Pingchen Zhang, Penglie Johnson, Daniel Powers, Jay Jaen, Juan Charo, Israel Schall, Thomas J. |
| author_facet | Bekker, Pirow Dairaghi, Daniel Seitz, Lisa Leleti, Manmohan Wang, Yu Ertl, Linda Baumgart, Trageen Shugarts, Sarah Lohr, Lisa Dang, Ton Miao, Shichang Zeng, Yibin Fan, Pingchen Zhang, Penglie Johnson, Daniel Powers, Jay Jaen, Juan Charo, Israel Schall, Thomas J. |
| author_sort | Bekker, Pirow |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6319730 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-63197302019-01-19 Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study Bekker, Pirow Dairaghi, Daniel Seitz, Lisa Leleti, Manmohan Wang, Yu Ertl, Linda Baumgart, Trageen Shugarts, Sarah Lohr, Lisa Dang, Ton Miao, Shichang Zeng, Yibin Fan, Pingchen Zhang, Penglie Johnson, Daniel Powers, Jay Jaen, Juan Charo, Israel Schall, Thomas J. PLoS One Correction Public Library of Science 2019-01-04 /pmc/articles/PMC6319730/ /pubmed/30608991 http://dx.doi.org/10.1371/journal.pone.0210593 Text en © 2019 Bekker et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Bekker, Pirow Dairaghi, Daniel Seitz, Lisa Leleti, Manmohan Wang, Yu Ertl, Linda Baumgart, Trageen Shugarts, Sarah Lohr, Lisa Dang, Ton Miao, Shichang Zeng, Yibin Fan, Pingchen Zhang, Penglie Johnson, Daniel Powers, Jay Jaen, Juan Charo, Israel Schall, Thomas J. Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study |
| title | Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study |
| title_full | Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study |
| title_fullStr | Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study |
| title_full_unstemmed | Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study |
| title_short | Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study |
| title_sort | correction: characterization of pharmacologic and pharmacokinetic properties of ccx168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319730/ https://www.ncbi.nlm.nih.gov/pubmed/30608991 http://dx.doi.org/10.1371/journal.pone.0210593 |
| work_keys_str_mv | AT bekkerpirow correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT dairaghidaniel correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT seitzlisa correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT leletimanmohan correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT wangyu correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT ertllinda correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT baumgarttrageen correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT shugartssarah correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT lohrlisa correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT dangton correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT miaoshichang correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT zengyibin correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT fanpingchen correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT zhangpenglie correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT johnsondaniel correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT powersjay correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT jaenjuan correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT charoisrael correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy AT schallthomasj correctioncharacterizationofpharmacologicandpharmacokineticpropertiesofccx168apotentandselectiveorallyadministeredcomplement5areceptorinhibitorbasedonpreclinicalevaluationandrandomizedphase1clinicalstudy |